CADASIL mutant NOTCH3(R90C) decreases the viability of HS683 oligodendrocytes via apoptosis

Mibo Tang1,2, Changhe Shi1, Bo Song1

  • 1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.

Insights

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) may involve direct glial cell defects. Mutant NOTCH3 in oligodendrocytes impacts cell viability, apoptosis, and autophagy, suggesting a new therapeutic target for white matter pathology.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a hereditary small vessel disease linked to NOTCH3 mutations.
  • Current models primarily attribute CADASIL pathology to vascular defects, with demyelination considered secondary.
  • NOTCH3 expression in mature oligodendrocytes suggests potential direct glial involvement.

Purpose of the Study:

  • To investigate the direct impact of mutant NOTCH3 on oligodendrocyte function.
  • To characterize the effects of the CADASIL-associated NOTCH3(R90C) mutation in HS683 oligodendrocytes.

Main Methods:

  • HS683 oligodendrocytes were transfected with wild-type NOTCH3, mutant NOTCH3(R90C), or control vector.
  • Techniques included immunoblotting, immunofluorescence, RT-PCR, and flow cytometry.
  • Assessed protein processing, cell viability, apoptosis, autophagy, and oxidative stress.

Main Results:

  • Mutant NOTCH3(R90C) exhibited aberrant proteolytic processing in oligodendrocytes.
  • Cells expressing NOTCH3(R90C) showed reduced viability and increased apoptosis compared to wild-type.
  • Elevated levels of intrinsic and extrinsic apoptosis, and autophagy were observed with NOTCH3(R90C) expression.

Conclusions:

  • Mutant NOTCH3 directly affects oligodendrocyte function, contributing to white matter pathology in CADASIL.
  • These glial defects may occur independently of or alongside vascular pathology.
  • Targeting NOTCH3-mediated glial dysfunction presents a potential therapeutic strategy for CADASIL.